Pephexia Therapeutics ApS - CVR: 41319208

2022, DKK

22.05.2023

Bruttoresultat

-5.266'

Primær drift

-7.864'

Årets resultat

-6.677'

Aktiver

9.746'

Kortfristede aktiver

9.746'

Egenkapital

-7.146'

Afkastningsgrad

-81 %

Soliditetsgrad

-73 %

Likviditetsgrad

220 %

Resultat

22.05.2023

Årsrapport	2022 22.05.2023	2021 17.05.2022	2020 26.04.2021
Nettoomsætning		626.000
Bruttoresultat	-5.266.259	0	0
Bruttoresultat	0	-4.738.037	-146.499
Resultat af primær drift	-7.864.015	-5.598.838	-146.499
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0
Finansielle indtægter	19.137	1.126	0
Finansieringsomkostninger	-705.614	0	0
Andre finansielle omkostninger	0	-116.713	-5.407
Resultat før skat	-8.548.065	-5.713.083	-151.906
Resultat	-6.677.466	-4.532.328	-129.817
Forslag til udbytte	0	0	0

Aktiver

22.05.2023

Årsrapport	2022 22.05.2023	2021 17.05.2022	2020 26.04.2021
Kortfristede varebeholdninger	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	3.099.392	1.283.286	81.322
Likvider	6.647.008	3.528.850	707.036
Kortfristede aktiver	9.746.400	4.812.136	788.358
Immaterielle aktiver og goodwill	0	0	143.556
Finansielle anlægsaktiver	0	0	0
Materielle aktiver	0	0	0
Langfristede aktiver	0	0	143.556
Aktiver	9.746.400	4.812.136	931.914

Aktiver

22.05.2023

Passiver

22.05.2023

Årsrapport	2022 22.05.2023	2021 17.05.2022	2020 26.04.2021
Forslag til udbytte	0	0	0
Egenkapital	-7.146.211	-2.652.069	794.775
Hensatte forpligtelser	0	0	31.582
Langfristet gæld til banker	0	0	0
Anden langfristet gæld	12.461.503	0	0
Leverandører af varer og tjenesteydelser	511.139	269.140	26.160
Kortfristede forpligtelser	4.431.108	374.671	105.557
Gældsforpligtelser	16.892.611	7.464.205	105.557
Forpligtelser	16.892.611	7.464.205	105.557
Passiver	9.746.400	4.812.136	931.914

Passiver

22.05.2023

Nøgletal

22.05.2023

Årsrapport	2022 22.05.2023	2021 17.05.2022	2020 26.04.2021
Afkastningsgrad	-80,7 %	-116,3 %	-15,7 %
Dækningsgrad	Na.	Na.	Na.
Resultatgrad	Na.	-724,0 %	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.
Egenkapitals-forretning	93,4 %	170,9 %	-16,3 %
Payout-ratio	Na.	Na.	Na.
Gældsdæknings-nøgletal	-1.114,5 %	Na.	Na.
Soliditestgrad	-73,3 %	-55,1 %	85,3 %
Likviditetsgrad	220,0 %	1.284,4 %	746,9 %

Resultat

22.05.2023

Gæld

22.05.2023

Årsrapport

22.05.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 22.05.2023)

Information om virksomhedens regnskabsklasse:The annual report for Pephexia Therapeutics ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

Beretning

22.05.2023

Dato for ledelsens godkendelse af årsrapporten:2023-05-15

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties connected with recognition or measurement The preparation of the financial statements requires an assesment in the validity of the going concern assumption. The management has reviewed projections for a period of 12 months from the date of approval of the financial statements as well as potential opportunities. Any potential short falls in funding have been identified and the steps to which the management is able to mitigate such scenarios and/or defer or curtail discretionary expenditures have been taken. The management recognises that there is a level of uncertainty as to going concern. However, the management has a reasonable expectaction that the company can maintain their existing credit facilities and if necessary expand these. Accordingly, the management believes it is appropriate to adopt going concern basis in the preparation of the financial statements.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Pephexia Therapeutics ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company Like previous years, the main activity of the company is to develop new medicines for the treatment of diseases and thereby achieve future revenues from research and development.